Home
About Us
About Boan
Culture
Our History
Our Team
Responsibility
R&D
Technology platform
Boan Product Pipeline
Intellectual Property
Production capacity
Products
News
Careers
People Strategy
Employee Stories
Development
Job Opportunities
Investors
Announcement & Circular
Corporate Governance
Financial Results
IR Activities
Contact IR
Contact us
简
/
繁
/
EN
News
Year
2021
2022
2023
2024
2025
Month
1
2
3
4
5
6
7
8
9
10
11
12
2025.08.08
Boyouping®, China’s First Locally Developed Dulaglutide Injection, Approved for Marketing
2025.07.15
Dr. Changlin Dou Appointed IFPMA ICH M18 Task Force Lead Expert
2025.06.17
Boan Receives FDA IND Clearance for Its CD228-Directed ADC
12
2025-06
Boan Grants Shaphar Right to Commercialize BA5101 in China
30
2025-04
Boan Biotech Presents Early Research Findings about Its Innovative Anti-CD25 Antibody (BA1106) at AACR Annual Meeting 2025
22
2025-04
Phase 3 Trial Results of Boan Biotech’s Dulagutide Injection Published in Journal of Diabetes
28
2025-03
Boan Biotech Announces 2024 Financial Results
27
2025-03
Boan Biotech's CD228 ADC Granted ODD by US FDA
20
2025-03
Boan Holds BPD Type 2b Meeting with FDA on BA1104
17
2025-02
Phase 3 Trial Results of Boan Biotech’s BA1102 (Denosumab Injection) Published in Journal of Bone Oncology
1
2
3
4
5
Follow me
鲁公网安备37069102000284
ICP备：鲁ICP备2021004064号-1
